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Abstract
Introduction We showed in a previous study that prenylated
proteins play a role in estradiol stimulation of proliferation.
However, these proteins antagonize the ability of estrogen
receptor (ER) α to stimulate estrogen response element (ERE)-
dependent transcriptional activity, potentially through the
formation of a co-regulator complex. The present study
investigates, in further detail, how prenylated proteins modulate
the transcriptional activities mediated by ERα and by ERβ.
Methods The ERE-β-globin-Luc-SV-Neo plasmid was either
stably transfected into MCF-7 cells or HeLa cells (MELN cells
and HELN cells, respectively) or transiently transfected into
MCF-7 cells using polyethylenimine. Cells deprived of estradiol
were analyzed for ERE-dependent luciferase activity 16 hours
after estradiol stimulation and treatment with FTI-277 (a
farnesyltransferase inhibitor) or with GGTI-298 (a
geranylgeranyltransferase I inhibitor). In HELN cells, the effect of
prenyltransferase inhibitors on luciferase activity was compared
after transient transfection of plasmids coding either the full-
length ERα, the full-length ERβ, the AF-1-deleted ERα or the AF-
2-deleted ERα. The presence of ERα was then detected by
immunocytochemistry in either the nuclei or the cytoplasms of
MCF-7 cells. Finally, Clostridium botulinum C3 exoenzyme
treatment was used to determine the involvement of Rho
proteins in ERE-dependent luciferase activity.
Results FTI-277 and GGTI-298 only stimulate ERE-dependent
luciferase activity in stably transfected MCF-7 cells. They
stimulate both ERα-mediated and ERβ-mediated ERE-
dependent luciferase activity in HELN cells, in the presence of
and in the absence of estradiol. The roles of both AF-1 and AF-
2 are significant in this effect. Nuclear ERα is decreased in the
presence of prenyltransferase inhibitors in MCF-7 cells, again in
the presence of and in the absence of estradiol. By contrast,
cytoplasmic ERα is mainly decreased after treatment with FTI-
277, in the presence of and in the absence of estradiol. The
involvement of Rho proteins in ERE-dependent luciferase
activity in MELN cells is clearly established.
Conclusions Together, these results demonstrate that
prenylated proteins (at least RhoA, RhoB and/or RhoC)
antagonize the ability of ERα and ERβ to stimulate ERE-
dependent transcriptional activity, potentially acting through
both AF-1 and AF-2 transcriptional activities.
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Introduction
Both estrogen receptor (ER) subtypes, ERα and ERβ, are
ligand-activated transcription factors. ERα is the major ER
in mammary epithelium and is an important regulator of cell
growth, differentiation and malignant transformation. After
binding to estrogen, the receptors associate with specific
estrogen response elements (EREs) within the promoters
of estrogen-regulated genes or the receptors affect the
activity of other transcription factor complexes such as AP-
1 (Jun–Fos). The two ER subtypes share affinity for the
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same ligands and DNA response elements [1]. These
nuclear receptors consist of six domains including the A/B
domain containing the AF-1 autonomous transcription acti-
vation domain, the C domain containing the DNA binding
domain, the E domain containing the ligand binding
domain, and the AF-2 ligand transcription activation domain
located in the C terminus of the receptor. Transcriptional
activation by ERα is mediated by the synergistic action of
the two distinct activation functions; although AF-1 is con-
stitutively active, it is usually weaker than the AF-2 activity.
In contrast, ERβ appears to have no significant AF-1 activity
and thus depends entirely on the ligand-dependent AF-2
activity [2].
The current model for ER action suggests that the ER mod-
ulates the rate of transcription through interactions with the
basal transcription machinery and by altering the recruit-
ment of co-activators that modify chromatin organization at
the promoter level of target genes [3-5]. In addition, tissue-
specific nuclear receptor co-activators and co-repressors
have been described that can modify the transcriptional
activity of the ER [6-8].
There is increasing evidence, however, that not all the bio-
logical effects of estrogens are mediated by direct control
of target gene expression; indeed, some effects are attrib-
uted to estrogenic regulation of signaling cascades [9-11].
Several rapid effects suggest that estrogens can interact
with receptors that are located in close proximity to the
plasma membrane [12,13]. These receptors, which appear
to form a subpopulation of the classical ER, are associated
with the cell membrane and are responsible for several
manifestations of estrogenic signaling [14,15]. Recent
data explain how the coordinate interactions between a
newly identified scaffold protein, MNAR, the ER and Src
lead to Src activation, demonstrating the integration of ER
action in Src-mediated signaling [11,13]. These data high-
light new evidence for a cross-talk between estradiol (E2)
and growth-factor-induced cytoplasmic signaling. Several
components of these signaling pathways are low molecular
weight GTPases, such as Ras, that require prenylation to
function.
Ras belongs to the Ras superfamily of low molecular
weight proteins. The activity of such proteins is controlled
by a GDP/GTP cycle. Members of the Ras superfamily
include the Ras, Rho and Rab subfamilies. The Ras and
Rho proteins of this superfamily are modified post-transla-
tionally by the isoprenoid lipids farnesylpyrophosphate and
geranylgeranylpyrophosphate. Farnesyltransferase and
geranylgeranyltransferase I respectively catalyze the cova-
lent attachment of the farnesyl group (C15) and the geran-
ylgeranyl group (C20) to the carboxyl-terminal cysteine of
prenylated proteins. Prenylation appears to be essential not
only for membrane association, but also for biological activ-
ity [16].
In a previous report, we demonstrated the implication of
both farnesylated and geranylgeranylated proteins in E2
actions, as prenylation inhibitors block the cell-cycle pro-
gression driven by E2 and stimulate the transcriptional
activity of the ER [17]. Our data strongly suggest that the
transcriptional stimulation of the ER by prenylation inhibi-
tors is due to a shift in the association of a transcription co-
regulator with the ERα. Among the numerous co-activators
identified to date, one of the best characterized is the p160
family of proteins including SRC-1, GRIP1 and RAC3,
which enhance ER transactivation by recruiting other tran-
scriptional regulatory factors such as CREB-binding pro-
tein and p300 (reviewed in [18]). We demonstrated that
both FTI-277 (a farnesyltransferase inhibitor) and GGTI-
298 (a geranylgeranyltransferase I inhibitor) increase the
association of the SRC-1 co-activator with ERα and that
FTI-277 decreases the association of HDAC1 with ERα,
which is essential for transcriptional repression.
In the present report, we assess in further detail the role of
prenylated proteins in the estrogenic regulation of tran-
scription in MCF-7 cells and in HeLa cells transiently
expressing ERα, ERβ or ERα mutants. Our data clearly out-
line that prenyltransferase inhibitors (FTI-277 and GGTI-
298) only stimulate ERE-dependent luciferase activity in
stably transfected MCF-7 cells. They stimulate both ERα-
mediated and ERβ-mediated ERE-dependent luciferase
activity, without any obvious relocation of the ER from the
cytoplasm to the nuclei. By contrast, the roles of both AF-1
and AF-2 of ERα appear to be determining in this effect.
These results further establish the involvement of pre-
nylated proteins, and more specifically the Rho-mediated
signaling pathway, in the negative regulation of ER tran-
scriptional activity.
Materials and methods
Materials
Materials used for cell culture were from InVitrogen Life
Technology (Cergy Pontoise, France). Polyethylenimine
was purchased from Sigma-Aldrich S.a.r.l. (St Quentin Fal-
lavier, France). FTI-277 and GGTI-298 were a generous
gift from S Sebti (University of South Florida, Tampa, FL,
USA). Both FTI-277 and GGTI-298 peptidomimetics were
dissolved in a solution of 10 mM dithiothreitol in
dimethylsulfoxide.
Cell culture
The MCF-7 human breast adenocarcinoma cell line was
obtained from the American Tissue Culture Collection
(Rockville, MD, USA). The development of stable transfect-
ants of MCF-7 cells (MELN cells) or HeLa cells (HELN
cells) has been described previously [19]. These cells wereAvailable online http://breast-cancer-research.com/content/7/1/R60
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established by transfecting MCF-7 cells or HeLa cells with
the ERE-β-globin-luc-SV-Neo plasmid and therefore
expressing luciferase in an estrogen-dependent manner.
MCF-7 cells were routinely cultured in RPMI 1640, and
MELN cells and HELN cells were cultured in DMEM growth
media, supplemented with 5% FCS. Cells were incubated
at 37°C in a humidified 5% CO2 incubator.
Cell transfection
Cells were grown for 3 days in phenol red-free medium,
containing 5% dextran-coated charcoal-treated fetal calf
serum (DCC-FCS). Then 6 × 104cells were seeded per
well in 12-well plates and grown for 1 day in phenol red-free
medium, containing 5% DCC-FCS. Cells were then trans-
fected (0.4 µg/well DNA, 1 µl/well polyethylenimine in a
final volume of 500 µl). Five hours after transfection, and for
optimal FTI-277 treatment, cells were pretreated for 24
hours with the farnesyltransferase inhibitor prior to receiv-
ing E2 (5 nM) and FTI-277 [17]. For GGTI-298 treatment,
no preincubation was performed and the inhibitor was
added simultaneously with E2. Control experiments were
also carried out; on the one hand in the absence of E2, and
on the other hand in the presence of E2 and in the absence
of inhibitors.
The plasmids used were the β-glob-Luciferase and the cor-
responding PGL3 empty vector for MCF-7 transient trans-
fection, pSG5-REβ coding the full-length ERβ, HGO
coding the full-length ERα, HG19 coding the AF-1-deleted
ERα, HG7 coding the AF-2-deleted ERα, and the pSG5
empty vector for transfection of HELN cells. The HG0,
HG19 and HG7 plasmids [20] were provided by Prof
Chambon (Institut de Génétique et de Biologie Moléculaire
et Cellulaire, Centre National de la Recherche Scientifique,
Strasbourg, France). The pRL-CMV Vector (Promega,
Charbonnières, France) coding the Renilla Luciferase was
co-transfected as a reporter gene.
Luciferase assay in cellular homogenates
Cells were seeded in 12-well plates as already described,
and were treated or not with prenyltransferase inhibitors
and E2 for 16 hours in a final volume of 500 µl. At the end
of the treatment, cells were washed with PBS and lysed in
100 µl lysis buffer (Promega). The luciferase activity from
both Luciferase genes was measured using the Dual Luci-
ferase Reporter (Promega), according to the manufac-
turer's instructions. For MELN cells that were not
transfected with the Renilla Luciferase gene, protein con-
centrations were measured using the Bradford technique
to normalize the luciferase activity data. A minimum of
15,000 relative light units were generated for the control
conditions, used as the reference onefold induction. For
each condition, average luciferase activity was calculated
from the data obtained from three independent wells.
ER immunocytochemical detection
For each condition, 5 × 105 MCF-7 cells were seeded onto
glass slides in 100 mm Petri dishes and were grown for 6
days in phenol red-free medium, containing 5% DCC-FCS.
Cells were then preincubated or not with farnesyltrans-
ferase inhibitor and received E2 (5 × 10-9 M) and/or inhibi-
tors 24 hours later. At the end of the treatment period (24
hours), cells were fixed in paraformaldehyde (4% in PBS)
for 1 min. The staining was performed by a Techmate Hori-
zon™ slide processor using a one-step peroxidase-conju-
gated polymer backbone visualization system (En Vision™
DAKO, Glostrup, Denmark) according to the manufac-
turer's instructions. The chromogenic substrate was 2,3'-
diaminobenzidine. The primary antibody used was a mono-
clonal anti-ERα antibody (clone 1D5; DAKO). Negative
controls were performed using the same staining technique
without incubation with the primary antibody. Data were
quantified using the ImageQuant software (Molecular
Dynamics, Inc., Sunnyvale, CA, USA). Results are
expressed in arbitrary units for either nuclei or cytoplasms
of analyzed cells, in each experimental condition.
Clostridium botulinum C3 exoenzyme treatment
MELN cells were grown for 3 days in phenol red-free
medium, containing 5% DCC-FCS. For each condition,
105 cells were seeded per well in 12-well plates and were
grown for 1 day in phenol red-free medium, containing 5%
DCC-FC. Cells were then treated with 20 µg/ml C3 exoen-
zyme (produced from the pGEX2T-C3 plasmid; kindly pro-
vided by Dr LA Feig, Tufts University School of Medicine,
Boston, MA, USA) in a final volume of 0.5 ml [21]. Cells
received E2 (5 × 10-9 M) 24 hours later and lysates were
obtained after a further 16 hours for the luciferase assay as
already described.
Statistical analysis
Statistical analysis of the data was conducted using an
unpaired two-sample t test. Significance was defined as P
< 0.02 or P < 0.05, as indicated in the text.
Results
Prenyltransferase inhibitors stimulate ERE-dependent 
luciferase activity in stably transfected MCF-7 cells but 
not in transiently transfected MCF-7 cells
We previously showed that both FTI-277 and GGTI-298
markedly enhance ER-mediated transcription in MELN cells
[17], a clone of MCF-7 cells stably transfected with the
ERE-β globin-luciferase reporter gene (Fig. 1a). After 5
days of E2 deprivation, cells were treated or not with 5 nM
E2, in the presence of or in the absence of prenyltrans-
ferase inhibitors, and the luciferase activity was quantified
16 hours later. For optimal FTI-277 treatments, a 24-hour
preincubation was systematically performed before E2
addition, whereas GGTI-298 was added simultaneously
with E2 [17]. We confirmed the efficiency and specificity ofBreast Cancer Research    Vol 7 No 1    Cestac et al.
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FTI-277 and GGTI-298 to inhibit protein prenylation in
MELN cells in these experimental conditions. Indeed, for
this purpose, we checked whether HDJ2, a farnesylated
protein, and Rap1A, a geranylgeranylated protein, were
indeed not prenylated in the presence of 10 µM FTI-277
and 5 µM GGTI-298, respectively (data not shown).
E2 alone induced a 14.7-fold increase in the luciferase
activity in MELN cells. In the absence of E2 (Fig. 1a, white
bars), FTI-277 and GGTI-298 stimulated the basal tran-
scriptional activity by 8.4-fold and 3.9-fold, respectively. In
the presence of E2 (Fig. 1a, grey bars), FTI-277 and GGTI-
298 dramatically enhanced the ability of E2 to stimulate
transcription by an additional 4.1-fold for FTI-277 and 2.5-
fold for GGTI-298. The ability of E2 to stimulate transcrip-
tion was statistically enhanced by both FTI-277 and GGTI-
298 (P < 0.02).
In parallel to this cell model, in which the Luciferase gene is
stably integrated into the genome, we determined the
effects of prenylation inhibitors in MCF-7 cells that were
transiently transfected with the ERE-β-glob-Luciferase
plasmid (Fig. 1b). In vehicle-treated cells, E2 still induced a
6.4-fold induction of luciferase activity. In the absence of
E2, FTI-277 and GGTI-298 only stimulated the basal tran-
scriptional activity by 3.2-fold and twofold, respectively. In
the presence of E2, the transcription was only enhanced by
an additional 1.1-fold for FTI-277 and 1.4-fold for GGTI-
298. The ability of E2 to stimulate transcription was not sta-
tistically enhanced by FTI-277 or by GGTI-298 (P < 0.05).
This result outlines the necessity of having a stably inte-
grated reporter gene in order to elicit the effects of prenyla-
tion inhibitors.
This necessity was confirmed by checking the effects of
FTI-277 in two other cell lines having a stably integrated
reporter system, beside the MELN cells. We used the
MVLN cells (MCF-7 cells stably transfected with an ERE-
vit-tk-luc plasmid [22]; data not shown) and HELN cells
(HeLa cells stably transfected with the ERE-β-globin-luc-
SV-Neo plasmid and transiently transfected with the ERα,
as described in Fig. 2). The data clearly indicate that in the
three models the farnesyltransferase inhibitor does stimu-
late the ERE-dependent luciferase activity, in the absence
of and in the presence of E2.
Prenyltransferase inhibitors stimulate both ERα-
mediated or ERβ-mediated ERE-dependent luciferase 
activity in HELN cells
We then examined whether the effects of prenylation inhib-
itors were preserved in cells that stably expressed the gene
coding the ERE-β glob-Luciferase but only transiently
expressed the ER. For this purpose we used HELN cells,
which are derived from the HeLa human cervical cancer
cell line. HELN cells have no endogenous ER but stably
Figure 1
Effects of prenyltransferase inhibitors on estrogen response element  (ERE)-dependent luciferase activity (a) in stably transfected MELN cells  and (b) in transiently transfected MCF-7 cells Effects of prenyltransferase inhibitors on estrogen response element 
(ERE)-dependent luciferase activity (a) in stably transfected MELN cells 
and (b) in transiently transfected MCF-7 cells. Both MELN cells and 
MCF-7 cells are deprived of estradiol (E2) for 4 days, and the MCF-7 
cells are transiently transfected with the ERE-β-glob-Luciferase and the 
Renilla luciferase plasmids. Three hours after transfection, cells were 
treated or not with FTI-277 (10 µM or dithiothreitol/dimethylsulfoxide 
vehicle). Twenty-four hours later, cells were stimulated with E2 (5 nM) 
or ethanol and were treated or not with FTI-277 or GGTI-298 (10 µM or 
5 µM, respectively, or dithiothreitol/dimethylsulfoxide vehicle). Luci-
ferase activity was quantified 16 hours after E2 addition, as described 
in Materials and methods. Results are expressed in arbitrary units after 
normalization. Error bars indicate the mean values ± standard deviation 
from triplicate experiments, and the results are representative of two 
independent experiments. Results obtained show that prenylation inhib-
itors statistically increase the luciferase activity induced by E2 com-
pared with the activity induced by E2 alone in MELN cells only (* P < 
0.02).
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express the gene coding the ERE-β glob-Luciferase [19].
As expected, we observed no induction of luciferase activ-
ity by E2 in cells transfected with the empty vector (Fig. 2).
For all experiments, luciferase activity was normalized
according to the expression of the co-transfected Renilla
Luciferase gene so as to take into account the variations
due to transfection efficiency.
HELN cells were then transfected with either ERα or ERβ.
In both cases, E2 induced the luciferase activity in vehicle-
treated cells (3.2-fold and 2.2-fold, for ERα-transfected
and ERβ-transfected cells, respectively), which was lower
than the activity obtained in MELN cells or MCF-7 cells
(14.7-fold and 6.4-fold, respectively). In the absence of E2
(Fig. 2, white bars), FTI-277 and GGTI-298 only weakly
stimulated the basal transcriptional activity by 3.6-fold and
2.4-fold, respectively, for ERα and by 1.5-fold and 1.7-fold,
respectively, for ERβ. These stimulations were statistically
significant (P < 0.05). In the presence of E2 (Fig. 2, grey
bars), FTI-277 and GGTI-298 enhanced the basal tran-
scriptional level by an additional 2.2-fold and 1.6-fold,
respectively, for ERα and by an additional 2.7-fold and 1.6-
fold, respectively, for ERβ. Altogether, the effect of E2 was
significantly enhanced by both prenylation inhibitors with
either ERα or ERβ (P < 0.05). As previously described for
MELN cells [17], these effects were strongly inhibited by
ICI 182,780 (data not shown).
Role of AF-1 and AF-2 in the effect of prenyltransferase 
inhibitors on ERE-dependent luciferase activity in HELN 
cells
In order to understand how prenylated proteins regulate ER
transcription, we investigated whether the effects of pre-
nylation inhibitors on transcription involve the AF-1 and/or
AF-2 functions of the ERα. For this purpose, we used
HELN cells that stably expressed the ERE-β glob-Luci-
ferase reporter gene and were transiently transfected with
plasmids coding either the full-length human ERα (HEG0)
or the ERα mutants with defective AF-1 (HEG19) or AF-2
(HEG7) activities [20].
Cells, deprived of E2 for 4 days, were co-transfected with
the Renilla luciferase plasmid and the plasmid coding full-
length ERα or its mutants (Fig. 3). As expected, E2 alone
could induce the luciferase activity only in cells transfected
with plasmids coding either the full-length human ERα
(HEG0) or the AF-1-defective mutant (HEG19). Indeed,
AF-1 is constitutively active, is ligand independent and is
mainly induced by growth factors. The absence of induc-
tion in cells transfected with the plasmid coding the AF-2
defective mutant (HEG7) is in agreement with the ligand
dependence of AF-2.
In the presence of E2 (Fig. 3, grey bars), FTI-277 and
GGTI-298 induced a statistically significant increase in the
stimulation of transcription by E2 by 2.3-fold and 1.6-fold,
respectively, in cells transfected with the full-length ERα
(HEG0) and by 1.9-fold and 2.3-fold, respectively, in cells
transfected with the AF-1 defective mutant (HEG19) (P <
0.02). In the absence of E2 (Fig. 3, white bars), FTI-277
and GTI-298 statistically increased the transcription of the
luciferase gene in cells transfected with plasmids coding
either the full-length human ERα or the two defective
mutants by twofold to threefold. Cells transfected with the
plasmid coding the AF-2 defective mutant (HEG7) exhib-
ited no significant induction of luciferase activity in the pres-
ence of the prenylation inhibitors compared with E2 alone.
Figure 2
Effects of prenyltransferase inhibitors on estrogen response element- dependent luciferase activity in HELN cells transfected with estrogen  receptor (ER) α or ERβ Effects of prenyltransferase inhibitors on estrogen response element-
dependent luciferase activity in HELN cells transfected with estrogen 
receptor (ER) α or ERβ. Cells, deprived of estradiol (E2) for 4 days, 
were co-transfected with the Renilla luciferase plasmid and either 
HEG0 (full-length ERα), pSG5-REβ (full-length ERβ) or pSG5 (empty 
vector). Five hours after transfection, cells were treated or not with FTI-
277 (10 µM or dithiothreitol/dimethylsulfoxide vehicle), and 24 hours 
later they were stimulated with E2 (5 nM) or ethanol and were treated 
or not with FTI-277 or GGTI-298 (10 µM or 5 µM, respectively, or dithi-
othreitol/dimethylsulfoxide vehicle). Luciferase activity was quantified 
16 hours after E2 addition, as described in Materials and methods. 
Results are expressed in arbitrary units after normalization. Error bars 
indicate the mean values ± standard deviation from triplicate experi-
ments, and the results are representative of three independent experi-
ments. Results obtained show that prenylation inhibitors statistically 
increase the luciferase activity on their own compared with control cells 
(white bars) and statistically increase the luciferase activity induced by 
E2 compared with the activity induced by E2 alone (grey bars) in MELN 
cells transfected with ERα or ERβ (* P < 0.05).
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The induction observed in cells transfected with the empty
vector in the presence of FTI-277 had no biological signifi-
cance as the final induction level was very low (1.2-fold).
Decreased cytoplasmic and nuclear presence of ERα due 
to prenyltransferase inhibitors in MCF-7 cells
To investigate the effects of prenylation inhibitors on ERα
localization within the cell, we detected the presence of
ERα by immunocytochemistry in MCF-7 cells, treated or
not with E2 and prenylation inhibitors for 24 hours. The
result of this experiment is shown in Fig. 4a, with the relative
quantification presented in Fig. 4b.
As expected, ERα is highly concentrated in the nuclei of the
untreated control with a significant staining of the corre-
sponding cytoplasms (indicated by arrows in Fig. 4a). In the
presence of E2, the staining intensity of both nuclei and
cytoplasms was clearly decreased, with no distinct staining
of the cytoplasms. In the absence of E2, similar decreases
in labeling intensity were observed in the cytoplasms and
nuclei of FTI-277-treated cells. Indeed, the presence of FTI-
277 dramatically enhanced the ability of E2 to decrease
nuclear staining, with the persistent absence of cytoplas-
mic staining. GGTI-298 similarly induced a decrease of
ERα staining intensity in the cell nuclei, although to a lesser
Figure 3
Effects of prenyltransferase inhibitors on estrogen response element-dependent luciferase activity in HELN cells, transfected with estrogen receptor  (ER) α or its mutants Effects of prenyltransferase inhibitors on estrogen response element-dependent luciferase activity in HELN cells, transfected with estrogen receptor 
(ER) α or its mutants. Cells, deprived of estradiol (E2) for 4 days, were co-transfected with the Renilla luciferase plasmid and either HEG0 (full-
length ERα), HEG19 (AF-1-deleted ERα), HEG7 (AF-2-deleted ERα) or pSG5 (empty vector). Five hours after transfection, cells were treated or not 
with FTI-277 (10 µM or dithiothreitol/dimethylsulfoxide vehicle), and 24 hours later they were stimulated with E2 (5 nM) or ethanol and treated or not 
with FTI-277 or GGTI-298 (10 µM or 5 µM, respectively, or dithiothreitol/dimethylsulfoxide vehicle). Luciferase activity was quantified 16 hours after 
E2 addition, as described in Materials and methods. Results are expressed in arbitrary units after normalization. Error bars indicate the mean values 
± standard deviation from triplicate experiments, and the results are representative of three independent experiments. Results obtained show that 
prenylation inhibitors statistically increase or do not statistically increase the luciferase activity on their own compared with control cells (white bars) 
and statistically increase the luciferase activity induced by E2 compared with the activity induced by E2 alone (grey bars) in HELN cells transfected 
with ERα or its mutants (* P < 0.02).
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extent than did FTI-277, both in the presence of and in the
absence of E2. Unexpectedly, no significant decrease in
the staining intensity was observed in the cytoplasms of
GGTI-298 treated cells, either in the presence of or in the
absence of E2.
It must be outlined that these effects were observed after
24 hours of treatment with the prenylation inhibitors,
whereas no effect was observed after short-term incuba-
tion (2 hours; data not shown).
Involvement of Rho proteins in ERE-dependent 
luciferase activity in MELN cells
C. botulinum C3 exoenzyme, a specific inhibitor of RhoA,
RhoB and RhoC proteins, was used to determine whether
the effects of prenylation inhibitors on ERE-mediated tran-
scription were due to Rho proteins. After 4 days of E2 dep-
rivation, cells were treated or not with C3 exoenzyme. E2
was added after 24 hours, and the luciferase activity was
quantified 16 hours later (Fig. 5). The inhibition of ADP-
ribosylation had already been examined under these
Figure 4
Immunocytochemical analysis of the effects of prenyltransferase inhibitors on estrogen receptor (ER) α distribution in MCF-7 cells Immunocytochemical analysis of the effects of prenyltransferase inhibitors on estrogen receptor (ER) α distribution in MCF-7 cells. (a) Cells, 
deprived of estradiol (E2) for 7 days, were treated or not with FTI-277 (10 µM or dithiothreitol/dimethylsulfoxide vehicle), and 24 hours later they 
were stimulated with E2 (5 nM) or ethanol and treated or not with FTI-277 or GGTI-298 (10 µM or 5 µM, respectively, or vehicle). After 24 hours, 
cells were fixed and stained. One randomly selected field is presented for each treatment. (b) Data were quantified by determining the grey value of 
both the nucleus and the cytoplasm for each cell counted, as described in Materials and methods. For each experimental condition, six randomly 
selected fields were analyzed. The total number of cells present in the fields ranged from 250 to 400. Error bars indicate the mean values ± standard 
error of the mean, and the results are representative of two independent experiments.
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conditions, demonstrating that the C3 exoenzyme does
enter the treated cells (data not shown). The results clearly
show an induction of luciferase activity by the C3 exoen-
zyme, in the presence of or in the absence of E2. This dem-
onstrates the involvement of Rho proteins in the negative
control of the ERE-dependent luciferase activity.
Discussion
Activation of ERs by estrogens triggers both ER nuclear
transcriptional activity and the Src/Ras/Erks pathway-
dependent mitogenic activity [9,13]. Prenylated proteins
have been implicated in both estrogenic actions [17,23],
and the prenylated Rho GTPases are now considered
important modulators of ER transcriptional activity [24,25].
We previously demonstrated that prenylated proteins
antagonize the ability of ERα to stimulate ERE-dependent
transcriptional activity, potentially through the recruitment
of a co-regulator [17]. In the present report, we proved that
the stable integration of a plasmid coding the ERE-depend-
ent luciferase in MCF-7 cells, or in HeLa cells transfected
with the ERα gene, is necessary for FTI-277 and GGTI-298
effects. We did, however, observe a significant but
expected stimulation of luciferase activity by E2 alone in the
transiently transfected cells.
The need for a stable integration of the reporter system
suggests that integration in the cell genome, an optimal
chromatin environment of the ERE, and a precise low
number of copies of the gene of interest are relevant con-
ditions for the effects of the prenylation inhibitor, and con-
sequently for the prenylated protein role. More insight in the
interactions between the co-regulator complex in chroma-
tin and prenylated proteins will be possible by performing
chromatin immunoprecipitation experiments.
We chose HELN cells as a model of ER-free cells. These
cells are stably transfected with the plasmid coding the
ERE-dependent luciferase. Neither E2 nor prenylation
inhibitors had any effect on the luciferase activity in these
cells. In contrast, the ERE-dependent activation of tran-
scription induced in the presence of both prenyltransferase
inhibitors and reversed by the antiestrogen ICI 182,780
(data not shown) could be observed after transient trans-
fection of HELN cells with the ERα gene. The classical con-
sensus ERE is directly bound to ERα and ERβ, and at this
site ERβ is a weaker transactivator [3-5]. In the presence of
E2 and either ERα or ERβ, the comparison of the effects of
prenylation inhibitors revealed that prenylated proteins had
similar effects on the transcriptional activities of both ERs.
These results are in agreement with the fact that Rho GDIα,
a Rho guanine dissociation inhibitor that represses the
activity of Rho GTPases including RhoA, Rac1 and Cdc42,
has been shown to be a positive regulator of both ERα and
ERβ transcriptional activities in human osteosarcoma cells
[24]
It must be outlined, however, that there are important DNA
binding sites for ERs other than ERE [26,27] where ERβ
exerts different, or sometimes even opposite, effects to
ERα (e.g. at AP-1 and Sp-1 sites) [28,29]. Such differential
signaling between ERα and ERβ may exist with estrogen
and prenylated proteins at the AP-1 response element. As
it has been shown that AP1-mediated transcription is
downregulated by RhoB, then RhoB may to some extent
act on E2-mediated effects through this pathway [30].
Moreover, the activity of a number of transcription factors
that may determine the overall promoter activity of ERE-
containing genes is known to be altered by prenylated pro-
teins (e.g. SRF, NF-κB) [31-34].
Our data strongly suggest the involvement of AF-2 in the
transcriptional activation induced by prenylation inhibitors.
Indeed, significant luciferase activity in cells expressing the
AF-1 deleted mutant is observed in the presence of inhibi-
tors and in both the presence of and the absence of E2,
whereas the rates of induction observed in the AF-2-
deleted mutant in the presence of inhibitors are similar in
the presence of and the absence of E2. This is confirmed
by the fact that the effects of prenylation inhibitors are sim-
ilar on ERα and ERβ, whereas ERβ seems to have no sig-
nificant AF-1 activity and thus depends entirely on the
ligand-dependent AF-2 [2]. Interestingly, prenylated pro-
Figure 5
Effect of C3 exoenzyme on estrogen response element-dependent luci- ferase activity in MCF-7 cells Effect of C3 exoenzyme on estrogen response element-dependent luci-
ferase activity in MCF-7 cells. Cells, deprived of estradiol (E2) for 4 
days, were treated with C3 exoenzyme as described in Materials and 
methods. Twenty-four hours later the cells were stimulated with E2 (5 
nM) or ethanol. Luciferase activities were quantified 16 hours after E2 
addition, as described in Material and methods. Results are expressed 
in arbitrary units after protein normalization. Error bars indicate the 
mean values ± standard deviation from triplicate experiments, and the 
results are representative of two independent experiments.
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teins appear to also regulate ER in an AF-2-independent
manner, as the AF-2-deleted mutant did not completely
abolish the increase in ER transcriptional activity induced
by either FTI-277 or GGTI-298, with a significant stimula-
tion in the absence of E2. This is in agreement with the data
suggesting that induction of ER transactivation by RhoGDI
is mediated largely by an ER AF-2-dependent mechanism,
and to a lesser extent by an AF-2-independent mechanism
[25].
The process by which a portion of the classical ER relo-
cates to the cell membrane remains undetermined. Steroid
receptors rapidly shuttle between the nucleus and cyto-
plasm by active nuclear import and export mechanisms. In
the absence of identified post-translational modifications
that could be involved in the attachment of the ER to the
cell membrane, it is probable that membrane translocation
of the ER is facilitated by another protein such as caveolin-
1, which has been reported to interact with the ER [35].
Indeed, proteins of the Rho family (RhoA and Rac1) are tar-
geted to caveolae in fibroblasts and are retained there by
an unknown mechanism [36]. Moreover, p122, a GTPase
activating protein is localized in the caveolae of both fibrob-
lastic and epithelial cells, and plays an important role in
caveolin distribution through the reorganization of the actin
cytoskeleton [37].
The intracellular localization of MNAR and the way it traffics
around the cell with the ER is still to be determined. Pre-
nylated proteins may then modulate ER signaling through
each key step in the various pathways: membrane attach-
ment, translocation to the nucleus, stability, and genomic or
nongenomic activities. The mechanisms that are responsi-
ble for the effects of prenylation inhibitors could involve
modifications in the intracellular localization, or the level of
ER protein expression, which would facilitate transcription.
As an example, RhoA is a geranylgeranylated protein
known to stimulate the degradation of the cyclin-dependent
kinase inhibitor, P27kip. We previously demonstrated that
the ER protein and RNA expression levels in total cell
lysates are decreased by both FTI-277 and GGTI-298
treatment [17], and that ICI 182,780, a pure estrogen
antagonist, induces the rapid relocation of ERα to an insol-
uble nuclear fraction, followed by its degradation [38]. Fur-
thermore, the association of the SRC-1 co-activator to the
ER is increased by FTI-277 and GGTI-298 [17], and slows
the cytoplasm to nucleus mobility of ligand–ER complexes
[39].
Immunocytochemical analysis showed a clear decrease in
the intensity of ER staining in the nuclei of MCF-7 cells
treated with either E2 or with FTI-277, or both, with a con-
comitant decrease in cytoplasmic ER staining. It is impor-
tant to note that GGTI-298 has a much weaker effect,
mainly in the cytoplasm. This suggests that farnesylated
proteins predominantly maintain a high level of ER expres-
sion within the whole cell (either by repressing the degra-
dation of ER or by increasing its expression or stability),
whereas geranylgeranylated proteins could only stimulate
the nuclear expression of the ER. Such a mechanism must
be elucidated; indeed, the degradation of ERα induced by
E2 is dependent on the proteasome [40], as has already
been suggested for RhoB [41]. Since prenylation inhibitors
had no effect on ER localization after a short incubation
period in MCF-7 cells (2 hours; data not shown), we spec-
ulate that prenylated inhibitors act mainly by inhibiting
active regulatory prenylated protein rather than by activat-
ing inhibited proteins.
Our data strongly suggest that both farnesylated proteins
and geranylgeranylated proteins modulate ER-mediated
activities, through either a common pathway or a distinct
pathway. A special emphasis has already been placed on
the role of Rho GTPases, and especially RhoA, Rac1 and
cdc42, as ER-negative modulators in human osteosarcoma
and breast cancer cells [24]. RhoA may therefore be the
target of GGTI-298, explaining part of the described
effects. We evaluated the role of the RhoA, RhoB, or RhoC
proteins in the negative regulation of ER transcriptional
activity, using the C3 exoenzyme. This toxin inhibits the
three small GTPases through ADP-ribosylation. We could
therefore implicate Rho proteins, which are generally
geranylgeranylated, as negativ e  m o d u l a t o r s  o f  E R  t r a n -
scriptional activity in MCF-7 cells. As both farnesylated pro-
teins and geranylgeranylated proteins play a role in the
negative control of ER-mediated transcriptional activity,
many farnesylated proteins are potential candidates for the
stimulatory effects of FTI-277. Due to the absence of spe-
cific inhibitors of the GTPase activity of farnesylated pro-
teins, a more progressive screening of the numerous
farnesylated proteins is required to identify those that are
involved in the negative regulation of ER-mediated tran-
scriptional activity.
It is important to note that RhoB can be both farnesylated
and geranylgeranylated, which modifies the cellular locali-
zation of the protein. Indeed, farnesylated RhoB is located
at the plasma membrane and geranylgeranylated RhoB is
endosomal [42]. An increase in RhoB mRNA is observed in
some breast cancer cell lines [43]. In rat fibroblasts, it has
been shown that in the presence of farnesyltransferase
inhibitors, the antiproliferative effect is driven by the geran-
ylgeranylated form of RhoB [44]. Rho proteins and other
prenylated proteins may then modulate ER-mediated tran-
scription. Apart from the involvement of RhoGDI as a posi-
tive regulator of ER transactivation, it has been shown that
Brx, a guanine nucleotide exchange factor for Rho proteins
and member of the Dbl oncogene family, contains a nuclear
hormone receptor binding region. Brx affects ER-mediated
gene activation by a mechanism that is dependent on theBreast Cancer Research    Vol 7 No 1    Cestac et al.
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Cdc42Hs signaling pathway [45]. Moreover, constitutively
active forms of c-Raf and Rac synergistically enhance the
CREB-binding protein/p300-mediated increase of tran-
scription in T-cell activation signals [46]. Finally, a constitu-
tively active form of Cdc-42 induces H4 hyperacetylation in
chromatin [47].
Altogether, our data strongly suggest that several pre-
nylated proteins, either farnesylated or geranylgeranylated,
modulate ER signaling by repressing its transcriptional
activity and/or increasing its stability. The determination of
the exact Rho protein(s) involved in the effect we described
is a major step of the research we are currently performing
in the laboratory, in addition to the identification of the
potential ER co-regulators.
Conclusion
Targeting the estrogen signaling pathway has proved to be
of great value in the treatment of human breast cancer, and
current evidence suggests that such targets hold great
potential in the prevention of human breast cancer. Evalua-
tion of the multiple pathways that can cross-talk with estro-
gen signaling pathways should help improve our
understanding of some of the possible mechanisms of de
novo  and acquired tamoxifen resistance. Farnesyltrans-
ferase inhibitors are a new class of anticancer drugs that
are at present in phase III clinical evaluation [48-50]. We
previously showed that the combination of a farnesyltrans-
ferase inhibitor and tamoxifen may increase the antitumor
effect of either drug alone in breast cancer [23]. Gaining
further insight into the involvement of prenylated proteins in
the estrogen signaling pathways should allow a more
rational approach to treating and/or preventing hormone-
resistant phenotypes.
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